USA Bollinger Band Signals Bullish Stocks: $VIE $RVNC $QURE

The Market Signal was created as a platform to help investors, if you own (NASDAQ:VIE), (NASDAQ:RVNC) or (NASDAQ:QURE) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/ Free-Report/NOW

(Click link above or copy, paste and hit enter in your browser for your report)

Viela Bio Reports Net Loss Of $38.9 Million In Q2 2020

https://themarketsignal.com/Free-Report/VIE

(Click link above or copy, paste and hit enter in your browser for your report)

Viela Bio Inc. (NASDAQ:VIE) 20 Days Bollinger Band $29.93 is below the last trading price, and the price currently looks bullish. The company reported a net loss of $38.9 million in Q2 2020 compared to a net loss of $5.5 million a year ago. At the end of the quarter, the company has cash and cash equivalents of $448.4 million with no outstanding debt. The company completed an underwritten public offering in June of 3.6 million common shares at $47 per share for gross proceeds of around $169.2 million.

During the quarter the company received FDA approval for UPLIZNA in the US. The company has continued to advance UPLIZNA development in the US for indications such as IgG4-related disease.

Revance Therapeutics Announces Results Of SAKURA 3 Study

https://themarketsignal.com/Free-Report/RVNC

(Click link above or copy, paste and hit enter in your browser for your report)

Revance Therapeutics Inc. (NASDAQ:RVNC) is also another stock whose price is looking bullish currently and its 20 Days Bollinger Band $23.21 is below the last trading price. The company has announced two peer-reviewed publications on the safety and efficacy of the SAKURA 3 open-label study in dermatologic surgery. Results from the study are consistent with those reported in SAKURA I and II studies for DaxibotulinumtoxinA in treating glabellar lines.

The company has also announced that its commercial team is already established in readiness to introducing the prestige aesthetics portfolio that includes the RHA(R) Collection of derma filters, HintMD fintech platform, and resilient hyaluronic acid in the US.

Uniqure To Report Revenue Of $126.48 Million In Current Fiscal Quarter

https://themarketsignal.com/Free-Report/QURE

(Click link above or copy, paste and hit enter in your browser for your report)

Another stock that is currently looking bullish is Uniqure NV (NASDAQ:QURE) whose 20 Days Bollinger Band $37.24 is below the last trading price. According to Zacks Investment Research, the company is expected to post sales of $126.48 million in the current fiscal quarter with four analysts estimating sales to be between $2 million and $451.3 million. Uniqure will report the result son on October 26, 2020. Full-year sales are estimated to be around $233.91 million.

Recently the company appointed Ricardo Dolmetsch as its Research and Development President effective September 14, 2020. Dolmetsch will replace Sander Van Deventer who moves to the role of Chief Medical Officer of the company.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_370982502/2705/2020-09-09T07:09:56

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.